Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling

Blood (2023) 142 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2023-184432

Published: 2023

Journal Articles

Maintenance Therapy with Chidamide Plus Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia Patients

Xiaohui Hu, Depei Wu, Suning Chen, Yaxue Wu, Yang Zhang, Lian Bai, Bing Wu, Haixia Zhou, Mingzhu Xu, Shanshan Jiang, Chongsheng Qian, Shengli Xue

Blood (2023) 142 (Supplement 1): 4991.

https://doi.org/10.1182/blood-2023-182570

Published: 2023

Journal Articles

Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Man Qiao, Xiaofei Yang, Xiebing Bao, Jihao Zhou, Han Zhu, Yanming Zhang, Tao You, Huiying Qiu, Ying Wang, Shengli Xue, Aining Sun, Yue Han, Xiao Ma, Xiaojin Wu, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 4922.

https://doi.org/10.1182/blood-2023-189348

Published: 2023

Journal Articles

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Jing Lu, Shengli Xue, Ying Wang, Hai-Ping Dai, Xuefeng He, Xiaohui Hu, Miao Miao, Huiying Qiu, Han Yue, Caixia Li, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 970.

https://doi.org/10.1182/blood-2023-181347

Published: 2023

Journal Articles

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Liqing Kang, Shengli Xue, Xiaowen Tang, Xiaoyan Lou, Chongsheng Qian, Wenjie Gong, Mingzhu Xu, Haixia Zhou, Zhen Yao, Wei Wang, Minghao Li, Nan Xu, Zhou Yu, Suning Chen, Huiying Qiu, Haiping Dai, Yang Xu, Depei Wu, Lei Yu

Blood (2023) 142 (Supplement 1): 3477.

https://doi.org/10.1182/blood-2023-181552

Published: 2023

Journal Articles

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Blood (2023) 142 (Supplement 1): 889.

https://doi.org/10.1182/blood-2023-172615

Published: 2023

Journal Articles

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Han-Yu Cao, Lu-Lu Chen, Chao-Ling Wan, Xiao-Hui Hu, Bing Wu, Li Yang, Li Wang, Yang Zhang, De-Pei Wu, Hai-Ping Dai, Hao Zhang, Shengli Xue

Blood (2023) 142 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2023-179733

Published: 2023

Journal Articles

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Sining Liu, Qingya Cui, Zheng Li, Wei Cui, Mengyun Li, Huiying Qiu, Shengli Xue, Suning Chen, Zhengming Jin, Miao Miao, Yue Han, Ying Wang, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2023-186718

Published: 2023

Journal Articles

Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study

Yanyan Li, Haixia Zhou, Chaoling Wan, Mingzhu Xu, Chongsheng Qian, Tongtong Zhang, Haiping Dai, AiNing Sun, Depei Wu, Shengli Xue

Blood (2022) 140 (Supplement 1): 3212–3213.

https://doi.org/10.1182/blood-2022-168054

Published: 2022

Journal Articles

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Jundan Xie, Xiaofei Yang, Xiebing Bao, Hongjie Shen, Jiannong Cen, Li Yao, Xiaohui Hu, Qian Wu, Jingren Zhang, Xuefeng He, Xiaowen Tang, AiNing Sun, Hongchun Qiu, Shengli Xue, Ying Wang, Jianhong Fu, Huiying Qiu, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 1439–1440.

https://doi.org/10.1182/blood-2022-166384

Published: 2022

Journal Articles

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Qian Wang, Haiping Dai, Wenzhi CAI, Qinrong Wang, Zhu Mingqing, Lingzhi Yan, Yan Yu, Hongjie Shen, Yang Xu, Ying Wang, Miao Miao, Shengli Xue, Yue Han, Xiaowen Tang, Huiying Qiu, Aining Sun, Jinyan Huang, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 9198–9200.

https://doi.org/10.1182/blood-2022-156862

Published: 2022

Journal Articles

Mutation Spectrum of FLT3 and Significance of Non-Canonical FLT3 Mutations in Hematological Malignancies

Shuai-Shuai Ge, Xiangdong Shen, Tianmei Wu, Jiahui Du, Haiping Dai, Qiaocheng Qiu, Songbai Liu, Depei Wu, Shengli Xue

Blood (2022) 140 (Supplement 1): 1425–1426.

https://doi.org/10.1182/blood-2022-159960

Published: 2022

Journal Articles

Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia

Yan Qiu, Chong-Sheng Qian, Hai-Xia Zhou, Ming-Zhu Xu, Li-Qing Kang, Ai-Ning Sun, De-Pei Wu, Lei Yu, Shengli Xue

Blood (2022) 140 (Supplement 1): 10337–10338.

https://doi.org/10.1182/blood-2022-164636

Published: 2022

Journal Articles

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Suning Chen, Jundan Xie, Xiaofei Yang, Hongjie Shen, Jiannong Cen, Li Yao, Xiaohui Hu, Qian Wu, Jingren Zhang, Hongchun Qiu, Xiaowen Tang, Aining Sun, Shengli Xue, Ying Wang, Huiying Qiu, Depei Wu

Blood (2021) 138 (Supplement 1): 35.

https://doi.org/10.1182/blood-2021-153288

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Blood (2021) 138 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2021-152927

Published: 2021

Journal Articles

Impact of FLT3 -ITD Remission Depth in Acute Myeloid Leukemia Patients Prognosis Prediction before Allogeneic Hematopoietic Cell Transplantation

Xiaoyu Xu, Hongjie Shen, Jia Chen, Xiaowen Tang, Shengli Xue, Xu Yang, Qiaocheng Qiu, Zixuan Ding, Suning Chen, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 262.

https://doi.org/10.1182/blood-2019-130381

Published: 2019

Journal Articles

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Liqing Kang, Xiaowen Tang, Nan Xu, Minghao Li, Jingwen Tan, Wei Qi, Zhou Yu, Xiaoyan Lou, Shengli Xue, Xin Li, MD, Jian Zhang, MD, Jia Chen, MD, Zhenkun Wang, PhD, Caixia Li, Fu Cheng Cheng, MD PhD, Depei Wu, MD PhD, Lei Yu, MD PhD

Blood (2019) 134 (Supplement_1): 2621.

https://doi.org/10.1182/blood-2019-132067

Published: 2019

Journal Articles

MVP Combined with FC As Lymphocyte-Depleting Chemotherapy before CAR-T Treatment Can Reduce the Incidence of Severe Cytokine Release Syndrome for Relapsed/Refractory ALL Patients with High Tumour Burden

XiaoWen Tang, MD, Zheng Li, Ting Xu, Haiping Dai, Jia Yin, Xiaopeng Tian, Shengli Xue, Yang Xu, MD PhD, Xiaming Zhu, Liqing Kang, Yujie Xia, Lei Yu, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5041.

https://doi.org/10.1182/blood.V130.Suppl_1.5041.5041

Published: 2017

Journal Articles

Ikaros Family Zinc Finger 1 Mutation Is a Poor Prognosis Factor of Adult B Cell Acute Lymphoblastic Leukemia

Shanhao Tang, Hongjie Shen, Xinliang Mao, MD PhD, Haiping Dai, Xiaming Zhu, Shengli Xue, Zixuan Ding, Jing Lu, Depei Wu, MD, XiaoWen Tang, MD

Blood (2017) 130 (Supplement 1): 5117.

https://doi.org/10.1182/blood.V130.Suppl_1.5117.5117

Published: 2017

Journal Articles

HLA-Haploidentical Donors Seem to be Not Inferior to HLA-Identical Sibling Donors for Hematopoietic Stem Cell Transplantation of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)?

Feng Chen, Depei Wu, MD PhD, XiaoWen Tang, MD, Miao Miao, Chengcheng Fu, Huiying Qiu, Shengli Xue, Xiao Ma, Zhengming Jin

Blood (2016) 128 (22): 5867.

https://doi.org/10.1182/blood.V128.22.5867.5867

Published: 2016

NARROW

All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling

Maintenance Therapy with Chidamide Plus Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia Patients

Sitagliptin for Prevention of aGVHD in Patients Received Alternative Donor Transplantations: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Mutation Spectrum of FLT3 and Significance of Non-Canonical FLT3 Mutations in Hematological Malignancies

Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Impact of FLT3 -ITD Remission Depth in Acute Myeloid Leukemia Patients Prognosis Prediction before Allogeneic Hematopoietic Cell Transplantation

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

MVP Combined with FC As Lymphocyte-Depleting Chemotherapy before CAR-T Treatment Can Reduce the Incidence of Severe Cytokine Release Syndrome for Relapsed/Refractory ALL Patients with High Tumour Burden

Ikaros Family Zinc Finger 1 Mutation Is a Poor Prognosis Factor of Adult B Cell Acute Lymphoblastic Leukemia

HLA-Haploidentical Donors Seem to be Not Inferior to HLA-Identical Sibling Donors for Hematopoietic Stem Cell Transplantation of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only